Search clinical trials for: ARQ197

Total 42 results

Kyowa Kirin Co., Ltd.

Completed

A Phase 1 Study of ARQ 197 in Patients With Solid Tumors

Cancer
Istituto Oncologico Veneto IRCCS

Terminated

TIvantinib as Maintenance Treatment in Extended Small-cell Lung Cancer (TIMES) (TIMES)

Carcinoma, Small Cell

Italy
Daiichi Sankyo, Inc.
ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary...

Completed

Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy (METIV-HCC)

Hepatocellular Carcinoma

United States, France, Italy, Germany, Spain, Switzerland, Belgium, Portugal, Netherlands, Australia, Brazil, Canada, Austria, New Zealand, Sweden, Argentina
Kyowa Kirin Co., Ltd.

Completed

A Randomized Double-blind, Placebo-controlled Japanese Phase III Trial of ARQ 197 in Hepatocellular Carcinoma (HCC) (JET-HCC)

Liver Cancer

Japan
Armando Santoro, MD

Completed

Study of Tivantinib (ARQ 197) Plus Cetuximab in EGFR Inhibitor-Resistant MET High Subjects

Colorectal Cancer Metastatic | C-met Overexpression

Italy
Novartis

Completed

Safety and Immunogenicity of Three Formulations of Vi-CRM197 Vaccine Against S. Typhi in Adults (18-40 Years Old)

Typhoid Fever

Belgium
Novartis Vaccines

Completed

Safety and Immunogenicity Evaluation After One or Two Doses of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants and Toddlers

Meningococcal Meningitis

Germany
Novartis

Completed

Extension Study of H01_04TP to Evaluate the Booster Response Induced by Vi-CRM197 in Adults

Typhoid Fever

Belgium
Daiichi Sankyo, Inc.
ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary...

Terminated

Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer

Non Squamous, Non-small-cell Lung Cancer

Poland, France, Germany, Italy, Spain, Canada, United States, Argentina, Belgium, Mexico, Australia, Russian Federation, Netherlands, Peru, Brazil, Austria, United Kingdom, Sweden, Czechia, Chile, Denmark, Hungary, Romania
Novartis

Completed

Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adult (18-40 Years Old)

Typhoid Fever

Belgium
Novartis Vaccines

Completed

Persistency Study After Hib-CRM (Cross-Reacting Material)197 or Hib-TT (Tetanus Toxoid) Vaccines in Chinese Children

Meningitis, Epiglottitis, Pneumonia, Arthritis Caused by Haemophilus Influenzae Type b

China
Imperial College London
ANRS, Emerging Infectious Diseases; Minka Therapeutics

Completed

3Sm Challenge Model Protocol

Healthy

United Kingdom
The Immunobiological Technology Institute (Bio-Manguinhos)...

Unknown

Conjugate Vaccine Against Meningococcus C a Brazilian Project

Serogroup C Meningococcal Meningitis

Brazil
National Institute of Allergy and Infectious Diseases...

Completed

A Phase IIb, Open-Label, Dose Ranging Study of 13-Valent Pneumococcal Conjugate Vaccine in Adults 55 Through 74 Years of Age Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine

Pneumococcal Infection

United States
Novartis Vaccines
Novartis

Completed

Evaluation of Meningococcal ACWY Immune Response in Children Aged 40 and 60 Months

Meningococcal Disease

Canada, United Kingdom
Aramis Biosciences, Inc.

Completed

A Study to Evaluate the Safety, Tolerability, and Efficacy of A197 in Subjects With Dry Eye Disease

Dry Eye Disease

United States
Finnish Institute for Health and Welfare
Merck Sharp & Dohme LLC; Wyeth-Lederle Vaccines; Pasteur Merieux Connaught

Completed

Efficacy Trial of Two Pneumococcal Conjugate Vaccines (PncCRM and PncOMPC) for Prevention of Acute Otitis Media Due to Vaccine Serotypes

Pneumococcal Infections | Otitis Media

Finland
Mitsubishi Tanabe Pharma Corporation

Completed

Exploratory Clinical Study of MT-2301

Haemophilus Influenza Type b

Japan
CanSino Biologics Inc.
Henan Center for Disease Control and Prevention

Completed

Phase I Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above (PICTPCV13i)

Pneumococcal Infections | Bacterial Infections | Streptococcal Infections

China
CanSino Biologics Inc.
Henan Center for Disease Control and Prevention

Completed

Phase III Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above (PICTPCV13i)

Pneumococcal Infections | Bacterial Infections | Streptococcal Infections

China
Pfizer

Completed

Safety and Immunogenicity Study of MenC-TT Vaccine (NeisVac-C) in Toddlers Previously Immunized With PCV7 (Prevenar®)

Neisseria Meningitidis (Bacterial Meningitis) | Invasive Pneumococcal Disease (IPD)

Germany
The Jackson Laboratory
University of Alabama at Birmingham; UConn Health

Completed

Genomics and Epigenomics of the Elderly Response to Pneumococcal Vaccines

Pneumonia | Aging

United States
Novartis

Completed

Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Children, Older Infants and Infants

Typhoid Fever

Philippines
Novartis

Completed

Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adults, Children, Older Infants and Infants

Typhoid Fever

Pakistan, India
Sanofi Pasteur, a Sanofi Company

Completed

A Phase I, Randomized, Modified Single-blind, Active-controlled (Infants Only), Four-stage, Step-down, Comparative, Multi-center Study

Meningococcal Immunization
Pfizer

Active, not recruiting

Long-Term PF-06651600 for the Treatment of Alopecia Areata (ALLEGRO-LT)

Alopecia Areata

United States, Spain, China, Korea, Republic of, Taiwan, Australia, Canada, Germany, Czechia, Poland, Japan, United Kingdom, Mexico, Argentina, Chile, Colombia, Russian Federation
Sanofi Pasteur, a Sanofi Company

Completed

Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Children Aged 2 to 9 Years

Meningitis | Meningococcal Infections | Meningococcal Meningitis

United States, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers

Meningitis | Meningococcal Infection

United States
CanSino Biologics Inc.

Not yet recruiting

A Clinical Trial to Evaluate the Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to 55 Years

Meningococcal Meningitis

Indonesia
Novartis
Novartis Vaccines

Completed

Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants

Meningitis | Meningococcal Infection

United States, China, Costa Rica, Guatemala, Panama, Peru
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life

Measles | Rubella | Mumps | Measles-Mumps-Rubella Vaccine

Finland, Thailand, United States, Spain, Czechia, Puerto Rico, Malaysia
Sanofi Pasteur, a Sanofi Company

Completed

Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers (MET41)

Healthy Volunteers (Meningococcal Infection)

Puerto Rico, United States
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents

Meningitis | Meningococcal Infections | Meningococcal Meningitis

United States, Puerto Rico
Novartis Vaccines
Novartis

Completed

Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Infants

Prevention of Meningococcal Disease

Canada, United Kingdom
GlaxoSmithKline

Completed

Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age

Measles; Mumps; Rubella | Measles-Mumps-Rubella Vaccine

United States, Finland, Taiwan, Estonia, Puerto Rico
GlaxoSmithKline

Completed

This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized Vaccine

Rotavirus Infection | Rotavirus Vaccines

United States
Arbor Pharmaceuticals, Inc.

Completed

Adult Attention Deficit Hyperactivity Disorder (ADHD) Study With Amphetamine Sulfate

Attention Deficit Hyperactivity Disorder

United States
GlaxoSmithKline

Completed

Study to Evaluate GSK Biologicals' GSK2197870A Vaccine Given as Primary Course in Infants

Neisseria Meningitidis | Haemophilus Influenzae Type b

United Kingdom
Novartis Vaccines

Completed

Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study

Healthy

United Kingdom
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the Russian Federation and Mexico (MET33)

Healthy Volunteers (Meningococcal Infection)

Mexico, Russian Federation
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers

Healthy Volunteers (Meningococcal Infection)

United States, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants

Pertussis Immunisation | Diphtheria Immunisation | Tetanus Immunisation | Pneumococcal Immunisation | Hepatitis B Immunisation | Haemophilus Influenzae Type b Immunisation | Polio Immunisation | Measles Immunisation | Rubella Immunisation | Varicella Immunisation | Mumps Immunisation

United States, Canada, Honduras, Puerto Rico

Search clinical trials for: ARQ197

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Egypt

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations